Please login to the form below
Delinia
This page shows the latest Delinia news and features for those working in and with pharma, biotech and healthcare.
Syncona launches another cell therapy company, Treg specialist Quell
Previous deals saw Celgene swoop on Delinia and its Treg therapies for autoimmune conditions, paying $300m upfront for the company, while Eli Lilly paid $150m for co-development rights to a ... Delinia’s DEL106 acts as an interleukin-2 (IL-2) mutein Fc
Latest news
-
Celgene pays $300m upfront for immunology start-up Delinia
Celgene has made another bolt-on acquisition, paying $300m upfront and $475m in milestones for Delinia and its immunology and inflammation programmes. ... The scale of the deal is eye-opening given that Delinia's lead candidate is still in preclinical
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2017
960. Valeant. Sanpower Group. Divestment. Dendreon equity interest. 820. Delinia. Celgene.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
BMS appoints Saurabh Saha as senior VP, global head of translational medicine
chief executive officer of Delinia until its sale to Celgene.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- AstraZeneca’s mild combination asthma reliever approved in UK
- Powering Rapid Cognitive Analysis with AI
- AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma
- Healthware Group report on depression care in Italy highlights need for digital therapeutics
- Masking the truth
- The speed of science and the pace of comms
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Ketchum appoints Conor Nash as global chief financial officer and chief operating officer
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
